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Purpose: We performed an epidemiological study of orbital lymphoma in the United 
States to determine how histological subtypes confer differing prognosis, and understand 
other factors associated with survival. 
 
Methods: All patients in the Surveillance, Epidemiology and End Results database 
diagnosed with a histologically confirmed orbital lymphoma between 1973 and 2014 
were included. Exclusion criteria included diagnosis at autopsy and the presence of other 
malignancies. Measures included patient demographic information, histological subtype 
and treatment modalities. Outcomes included overall and disease specific survival.   
 
Results: Of the 1504 cases identified, 702 were male (46.7%, mean age: 64.4 years, 
standard deviation [SD]: 15.3) and 802 were female (53.3%, mean age: 67.5 years, SD: 
14.3). Mucosal associated lymphoid tissue (MALT) (49.5%) and diffuse large B cell 
lymphoma (DLBCL) (19.5%) were the two most common histologic subtypes. MALT 
lymphoma conferred the best prognosis (10-year cancer specific survival [CSS] 90.2%, 
95% Confidence Interval [CI] 87.4% – 93.1%) and DLBCL conferred the worst 
prognosis (10-year CSS 68.6%, 95% CI 62.5% – 75.3%) (p<0.001, log-rank test). Older 
age above 50 (Hazard Ratio [HR]: 3.71, 95% Confidence Interval [CI]: 2.94-4.66, 
p<0.001), male sex (HR: 1.22, 95% CI: 1.039-1.441, p = 0.015), no radiation (HR: 1.72, 
95% CI: 1.46-2.02, p<0.001) and DLBCL histology were significant predictors of worse 
overall survival. 
 
Conclusions: DLBCL histology confers the worst outcomes whereas MALT lymphoma 
confers the best outcome in orbital lymphoma. Age, gender, and radiation treatment also 
influence survival. These epidemiological results can be used clinically to communicate 
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Orbital lymphoma (OL) accounts for the majority of orbital malignancies in 
adults.1,2 However, it is still a rare disease, accounting for less than 1% of all Non-
Hodgkin’s Lymphoma (NHL).3 Due to its rarity, efforts to document its presentation and 
epidemiology have relied primarily on case reports or cohorts of patients pooled from 
around the world.2,4–11 Although, conjunctival and ocular adnexal lymphoma are thought 
to be along the same spectrum as OL, the prognosis of purely conjunctival lymphoma 
tends to be better.4 
 
 It has been observed that the various histologic subtypes of OL confer different 
overall survival rates.4,10–12 In the largest study reporting the effect of histologic subtype 
of OL on survival, Olsen et al found extranodal marginal zone B cell lymphoma (which is 
also known as Mucosa Associated Lymphoid Tissue [MALT] lymphoma) to confer the 
best prognosis and mantle cell lymphoma (MCL) to confer the worst prognosis in a 
cohort of 797 patients from seven international cancer centers.11 However, patients in the 
United States accounted for only 30% of their cohort and were included from only three 
regional cancer centers. Moreover, no subgroup analysis was performed in their study for 
survival amongst the American cohort. Although prognostication is of great importance 
in oncologic care, due to the rarity of this disease in the United States, there is no large 
study that provides prognostication by histological type of the disease. Although disease 
staging can currently offer prognostic value it is not as predictive of survival in OL as 
disease histology.10 Further survival data based off disease histology could offer more 




The earliest mention of “orbital lymphoma” in PubMed indexed journals dates 
back to 1965, when Jortay described a case of unilateral exophthalmos that was thought 
to be a chronic granuloma or orbital lymphoma.13 Reese et al in 1971 also identified 
orbital lymphomas compromising 10% of the 504 primary orbital tumors in their study 
whereas Henderson et al in 1974 diagnosed orbital lymphomas comprising 8% of their 
series of 465 orbital tumors. In Henderson’s studies, orbital lymphoma was seen in 
patients mostly younger than 20.14  
 
In 1978, Jakobiec and colleagues from the Harkness Eye Institute at Columbia-
Presbyterian Medical Center published a review of lymphoid lesions of the orbit, 
identifying 13 orbital lymphomas from 410 cases of orbital lymphoid lesions 
accumulated over 40 years in their pathology laboratory.15 They noted that the disease 
was more commonly occurring in older adults above the age of 50. Furthermore, they 
noted that the diagnosis and prognosis of these lesions was challenging for the clinician 
and the pathologist because of difficulty in identifying frankly neoplastic cellular details 
in the lesions and discerning whether the orbital lesion is primary or a manifestation of 
systemic diseases. In 8 of the 13 patients with initially presumed primary orbital 
lymphoma, metastasis to other sites was usually found at the time of diagnosis, with all 
cases having metastasized within 1 year and 3 months of initial diagnosis. Treatment of 
the disease involved radiotherapy with 2000-5000 rads (equivalent to 20-50 Gy), 
exenteration in some cases and systemic chemotherapy reserved for treatment resistant 
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tumors. Survival from time of diagnosis ranged from 5 months to 6 ½ years – the cause 
of death in all patients was directly related to the tumor or the side effects of treatment.15 
  
Disease Histopathologic Classifications  
WHO Classification  
 
Lymphomas are malignancies due to abnormal clonal proliferation of 
lymphocytes. Although there have been many classification systems in the past for 
lymphomas (which are covered later in this thesis), the most updated system is the WHO 
classification, which was majorly updated in 2016.16 In this classification, lymphomas 
can be divided into Hodgkin’s lymphoma, which consists of B-cells and Non-Hodgkin’s 
lymphoma which includes B-Cell, T-Cell and rarely NK cell lymphomas. These types 
can be further subdivided based on histo-cytologic criteria.10 There are over 40 sub-
categorizations, many of which are beyond the scope of this study due to the rarity of 
their occurrence in the orbit (for more information, see Caponetti and Bagg 2017).17 In 
particular, this thesis focuses on Non-Hodgkin B-Cell lymphomas – for more information 
on T cell lymphomas and beyond, see Olsen et al 2019, which is referenced in this 
thesis.10  
 
In the orbit, the following histological subtypes of NHL are frequently 
encountered: follicular lymphoma (FL - International Classification of Diseases for 
Oncology 3 [ICD-O-3]: 9695/3, 9690/3, 9691/3, 9698/3), extranodal marginal zone 
lymphoma of mucosal associated lymphoid tissue (MALT - ICD-O-3: 9699/3), diffuse 
large B cell lymphoma (DLBCL - ICD-O-3: 9680/3, 9684/3), lymphoplasmacytic 
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lymphoma (LPL - ICD-O-3:9671/3), small lymphocytic lymphoma (SLL - ICD-O-3: 
9670/3) and mantle cell lymphoma (MCL - ICD-O-3: 9673/3). Figure 1 demonstrates 
how these histological subtypes are categorized. 
 
 Follicular lymphomas (FL) are of B cell lineage that demonstrate follicular 
architecture. These follicles are uniform, densely packed to the point that they often 
obliterate nodal architecture. They are composed of proportions of small cleaved cells 
and some large cells that may or may not be cleaved. Grading of the lymphoma is based 
on the proportion of large cells, as seen in table 1. Disease staging is not based on 
histopathologic features but rather the Ann Arbor or AJCC Staging system, which will be 
discussed later.18 
 
Figure 1:WHO Classification of Non-Hodgkin Lymphomas. Grey boxes indicate histological types not found commonly 
in the orbit. Red indicates common orbital lymphoma histologies. FL=Follicular Lymphoma, SLL = Small Lymphocytic 
Lymphoma, MCL = Mantle Cell Lymphoma, LPL = Lymphoplasmacytic Lymphoma, MZL = Marginal Zone 
































Histopathologic Grade of Follicular Lymphoma  % of Large Cells 
1 Under 25 
2 25-50 
3 Over 50 
Table 1: Histopathologic Grading of Follicular Lymphomas 
 
 Marginal Zone Lymphomas are composed of small B lymphocytes with pale 
cytoplasm known as monocytoid cells. They have an affinity for mucosal sites, hence the 
designation of the specific subtype MALT lymphoma. These neoplastic cells may involve 
marginal zones of reactive follicles and colonize adjacent follicles. There is no consensus 
grading criteria for MALT lymphoma, but it is generally considered a ‘low grade’ 
neoplasm. Staging is based on the Ann Arbor criteria or the AJCC criteria.18 
 
 Small Lymphocytic Lymphoma, also known as chronic lymphocytic leukemia 
when identified in non-solid tumor form, is a neoplasm made of mostly small round B 
cells. Diagnostic criteria includes effacement of nodal architecture by sheets of small B 
lymphocytes, pseudo-follicular proliferation. There is no consensus grading criteria for 
this disease, but it is generally considered as a ‘low-grade’ neoplasm. Staging is based on 
the Ann Arbor criteria or the AJCC criteria.18 
 
 MCL is a B cell neoplasm containing small to medium sized cells with mild or 
moderate nuclear irregularities. The neoplasm commonly involves and expands the 
mantle zone and compressing the germinal center in a lymph node. A key feature of this 
subtype is its genetic expression of bcl1, which is discussed in the section on disease 
pathogenesis. There is no consensus grading criteria for MALT lymphoma, but it is 
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generally considered a ‘high grade’ neoplasm. Staging is based on the Ann Arbor criteria 
or the AJCC criteria.18 
 
 LPL is a B cell neoplasm composed of small round B cells that display prominent 
plasmacytoid differentiation. These cells also lack defining features of other small B cell 
lymphomas. Many cases can express IgM and cause hyper-viscosity syndromes. There is 
no consensus grading criteria for this neoplasm, though it is generally regarded as ‘low-
grade’. Staging is based on the Ann Arbor criteria or AJCC criteria.18 
 
 DLBCL is an aggressive neoplasm that consists of large cells that show a diffuse 
pattern of growth that effaces normal nodal architecture. Although there are no formal 
consensus grading criteria, it is considered ‘high grade.’ Staging is based off Ann Arbor 





 The Rappaport classification was amongst the earliest modern classifications used 
to describe lymphomas and was proposed in 1956. Henry Rappaport and colleagues 
argued for a clinically useful classification that was accurate, reproducible, easily taught 
and learned. Using these principles, they classified NHL into two subtypes: nodular, in 
which the neoplasm retained nodal architecture, and diffuse, which was characterized by 
effacement of the lymph node architecture.19 Furthermore, they subclassified neoplasms 
as ‘well-differentiated’, ‘poorly-differentiated’, and ‘histiocytic.’ This classification fell 
out of favor with the realization that all lymphomas were of lymphoid and not histiocyte 
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origin and the improvements in technology allowing for differentiate of B cell neoplasms 
from other lymphoid cells.  
 
 In 1974 Lukes and Collins proposed the first classification based on cellular 
origin and lymphocyte transformation alterations. This system did not consider cellular 
architecture but introduced terms to describe individual cells such as small and large, 
cleaved and uncleaved cells.  
 
 The Kiel Classification also built on the Lukes and Collins Classification and 
divided neoplasms into low- and high-grade variants based on cell maturity. This 




In 1994, the International Lymphoma Study Group devised a consensus list of 
lymphoid neoplasms, which were published as the ‘Revised European-American 
Classification of Lymphoid Neoplasms’ (REAL). This classification utilized a 
B Cell T Cell 
Low Grade Low Grade 
Lymphocytic- chronic lymphocytic and hairy cell 
leukemia  
Lymphocytic – chronic lymphocytic and 
prolymphocytic leukemia  
Lymphoplasmacytic/cytoid Lymphoepithelioid  
Plasmacytic  Angioimmunoblastic  
Centroblastic/centrocytic  T zone 
Centrocytic  Pleomorphic, small cell 
High Grade High Grade 
Centroblastic  Pleomorphic, medium and large cell 
Immunoblastic Immunoblastic 
Large cell anaplastic Large cell anaplastic 
Burkitt lymphoma Lymphoblastic  
Lymphoblastic   
Rare types Rare Types  
Table 2: Updated Kiel Classification (1988) 
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combination of morphologic, immunophenotype, genetic and clinical features to classify 
diseases as opposed to previous methods which insisted on just one ‘gold standard’ 
feature to guide classifications. These guidelines were thereafter modified slightly to 
produce the current WHO classification.19 
 
 Of note, since these various older classifications were based off different 
techniques and utilized different ‘gold standards,’ converting disease classifications from 
older case reports and databases is often not possible due to the lack of information 
available in those cases to reclassify the disease based on newer methods such as 
immunohistochemistry, genetics, and protein expression. 
 
Disease Pathogenesis 
Although lymphomas most often occur within lymph nodes, they can manifest 
extranodally in the conjunctiva, eyelids, lacrimal glands and the orbit. The pathogenesis 
of orbital lymphomas can be categorized into three main mechanisms: genetic 




MALT lymphoma of the orbit is associated with well described genetic 
abnormalities. At the chromosomal level, trisomy 3, 7, 12 and 18 as well as translocations 
t(11;18), q(21;21), t(1;14) (p22;q32), t(1;2), (p22;q12), t(14;18) (q32;q21), and t(3;14) 
(p14.1;q32) have been described in MALT lymphomas isolated from the ocular adnexa.10 
Most of these translocations affect cellular regulation and, in many cases, lead to the 
eventual activation of nuclear factor kB (NF-kB). This gene codes for a transcription 
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factor that is involved in immunologic signaling and is associated with numerous 
lymphoid malignancies. The A20 gene is a repressor of NF-kB and is also found to be 
downregulated in orbital lymphomas.10  
 
DLBCL is also often associated with similar mutations in genes that lead to NF-
kB activation downstream. Notably, this histology is also associated with overproduction 
of the anti-apoptotic protein bcl2, in particular due to the mutation t(14;18) (q32,q21), 
which is found in up to 34% of cases. This mutation is also found in FL which may 
account for some FLs transforming into DLBCLs.10 Other mutations associated with this 
subtype include translocations of MYC, EZH2, BCL6, and MEF2B genes, which are well 
known genes in tumorigenesis.  
 
MCL is characterized by the hallmark translocation mutation of 
t(11;14)(q13;q32). This leads to overproduction of the cellular proliferation factor Cyclin 
D-1.  
 
Other histological subtypes of orbital lymphomas also have many unique 
mutations, however, their role in disease pathogenesis is not fully understood and is still 




 Autoimmune phenomena is commonly associated with lymphoproliferative 
disorders and is a complex bidirectional process of active study.20 Many lymphomas 
 15 
present with paraneoplastic autoimmune diseases in addition to many autoimmune 
diseases preceding the onset of a lymphoproliferative disorder. In Non-Hodgkin’s 
Lymphoma (NHL), 70% of autoimmune diseases precede the onset of lymphoma. The 
major theory relating the two diseases asserts that there are common underlying genetic 
mutations that may drive unregulated proliferation of immune cells that are self-reactive 
and/or malignant.20 Increased risk of NHL of the orbit, especially DLBCL and MALT 
lymphoma, is reported in patients suffering from Sjogren’s syndrome, systemic lupus 
erythematosus, rheumatoid arthritis, Hashimoto’s thyroiditis, immune thrombocytopenic 
purpura, and autoimmune hemolytic anemia. In one case of orbital MALT lymphoma, 
treatment of the autoimmune disease with methotrexate led to resolution of the 
lymphoma without any further treatment.21  
 
Immunosuppressive Disorders  
 There is a well-established relationship between lymphomas and 
immunosuppressive states. Lymphoma is the most common cancer in patients infected 
with human immunodeficiency virus – in particular DLBCL manifests with a high 
frequency in this patient population.10 Furthermore, with treatment of the 
immunosuppression, in particular with the introduction of highly active antiretroviral 
therapy (HAART), the incidence of lymphoma has declined amongst patients with HIV.10 
Although the mechanism underlying this association is not well known, increased viremia 
amongst immunosuppressed patients, particularly with oncogenic viruses like Ebstein 
Barr Virus (EBV) may play a role in pathogenesis. Orbital lymphoma has also been seen 
in transplant patients as a rare manifestation of post-transplant lymphoproliferative 
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disorder. This form of the disease is treated with reduced immune suppression in addition 





 OL is a disease that primarily affects elderly patients. Though there are 
differences amongst the age distribution for various histological subtypes of the disease, 
73% of patients diagnosed with OL are over the age of 50.10 Notably, however, the age 
distribution of DLBCL is wider than other histological subtypes, with 20% of patients 
aged 40-49 years and 10% of patients aged younger than 40 years.  
 
 Although many case reports of orbital lymphoma in the past did not specify sex, 
in a recent multicenter retrospective study by Olsen et al, the authors noted no major 
difference in sex by histology with a roughly equal proportion of males and females. A 
notable exception to this was the MCL cohort, where men composed 73% of the cases.11 
Previous studies, although limited by their sample size, also observed a female 
preponderance in MALT lymphoma and FL, in addition to the male preponderance in 
MCL cases. 
  
Presenting Symptoms  
 
 Patients with orbital lymphoma present with various complaints, the most 
common of which is proptosis. Other symptoms include swelling, ptosis, diplopia, 
limited extraocular movement, pain, change in vision, erythema, chemosis, and B-
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symptoms (fever, weight loss, night sweats).10 Unilateral proptosis is especially 
concerning for an orbital tumor and should necessitate further imaging studies.   
Duration  
 The duration of symptoms before formal ophthalmological consultation and 
diagnosis varies widely based on the histological type of tumor. Low grade tumors tend 
to present late, with MALT, FL, and CLL having a mean duration of symptoms of 6.5, 24 
and 18 months respectively.10 By contrast, DLBCL has a duration of symptoms to 
consultation of weeks. However, some higher-grade lymphomas such as MCL have 
longer duration of symptoms up till 9 months until consultation is sought, implying 
slower growth. Sometimes, these patients may be initially treated with antibiotics for 
cellulitis, further delaying the diagnosis of lymphoma.  
 
Location  
 Most NHL lymphomas of the ocular adnexa present as a unilateral tumor. The 
exception to this is MCL, which presents bilaterally in 43% of patients and CLL, which 
presents bilaterally in 50% of cases.10  
  
 In terms of location within the orbit, tumors can either be extraconal or intraconal 
and can involve the extraocular muscles. Some tumors can involve more than one site. 
See Figure 2 for a schematic explanation of extraconal vs. intraconal. Most B cell 
lymphomas are located in the extraconal space (72%) and a majority of these involve the 
lacrimal glands as well (51%). 8% of tumors are in the intraconal space and 9% involve 
the extraocular muscles.10 
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Figure 2: Extraconal versus intraconal orbital lesions. Image courtesy of Martins et al. "Microsurgery of the Orbit: 
The Rule of Seven." Anatomy Research International. 2011 [Creative commons license] 
 
Tumors can be defined as primary lymphoma or secondary lymphoma. By 
definition, a tumor is primary if it is biopsy verified and the patient has no evidence of 
concurrent lymphoma in another site or any history of lymphoma. If a patient has 
evidence of distant neoplasms or a history of lymphoma, their OL is classified as 
secondary. 73% of B-cell lymphomas arise as primary tumors. MALT and FL are more 
likely to arise as primary tumors in the orbit whereas a large percentage of DLBCL and 
MCL manifest as secondary orbital tumors (42% and 41% respectively).10 Furthermore, 
DLBCL has a predilection to involve the periorbital bone whereas MALT lymphoma and 
FL are more likely to involve the conjunctiva (40% and 38% of cases respectively).10 
 
Disease Diagnosis and Workup 
 A full ophthalmologic evaluation alongside a complete physical examination is 
warranted whenever an orbital mass is suspected. If examination findings points towards 
an orbital tumor, imaging preferably with magnetic resonance imaging or a computed 
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tomography scan of the orbits is indicated. If a tumor is identified on imaging, an open 
biopsy is indicated for diagnostic confirmation.10 A fine needle biopsy is recommended 
against, since it may not produce an adequate sample in which nodal architecture is 
apparent.10 
  
 Histopathologic examination of the biopsy sample focuses on morphology, 
immunohistochemical properties and protein expression studies. These are undertaken to 
differentiate B-cell lymphomas from other rarer neoplasms, as well as identify specific 
histological subtypes of the disease.10 
 
Disease Staging  
Although the Ann Arbor staging criteria was originally designed for Hodgkin’s 
lymphoma, it is also very commonly used for staging NHL as well. There are 4 stages, 
which are determined by assessing lymph node and extra-nodal involvement (single node 
[or extra-nodal site] = stage I [I E], more than one node [or >1 extra-nodal site] = stage II 
[II E]), involvement on one or both sides of the diaphragm (if both sides involved = stage 
III) and disseminated metastasis (stage IV). This system is not very prognostically useful 
for orbital lymphomas since the orbit counts only as 1 extra-nodal site, leading to the vast 
majority of orbital lymphomas to be classified as stage I E, regardless of how locally 
aggressive the disease is.10  
 
In response to this issue, in 2009 the Ophthalmic Oncology Task Force of the 
American Joint Committee on Cancer (AJCC) devised a new staging system for ocular 
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adnexal lymphomas, that was based off the TNM staging criteria and allowed for finer 
delineation and better prognostication of orbit specific lymphomas. This system is 
outlined in table 3. 
 
Even though this updated staging system allowed for better prognostication and 
classification of the vast majority of OL patients previously classified as Ann Arbor 
Stage I E, patient disease free survival and recurrence were more closely related to the 
histopathological subtype rather than the tumor size or site-specific location, as outlined 

















Table 3: AJCC Staging Guidelines for Ocular Adnexal Lymphomas 7th Edition 
 
Treatment 
 The treatment of OL is coordinated by a multidisciplinary team including an 
ophthalmologist, a hematologist and a radiation oncologist. Due to significant variation in 
Primary Tumor (T) 
• TX: lymphoma extent not specified 
• T0: no evidence of lymphoma 
• T1: lymphoma involving the conjunctiva alone without orbital involvement 
• T1a: bulbar conjunctiva alone 
• T1b: palpebral conjunctiva, +/- fornix, +/- caruncle 
• T1c: extensive conjunctival involvement 
• T2: lymphoma with orbital involvement +/- any conjunctival involvement 
• T2a: anterior orbital involvement (+/- any conjunctival involvement) 
• T2b: anterior orbital involvement (+/- any conjunctival involvement but with lacrimal 
involvement) 
• T2c: posterior orbital involvement (+/- any conjunctival involvement, +/- anterior involvement, 
+/- any extraocular muscle involvement) 
• T2d: nasolacrimal drainage system involvement (+/- conjunctival involvement but not including 
nasopharynx) 
• T3: lymphoma with preseptal eyelid involvement (infiltrates preseptal tissues such as dermis or 
orbicularis muscle of anterior eyelid skin) +/- orbital involvement, +/- any conjunctival involvement 
• T4: orbital adnexal lymphoma extending beyond orbit to adjacent structures such as bone and brain 
• T4a: involvement of nasopharynx 
• T4b: osseous involvement (including periosteum) 
• T4c: involvement of maxillofacial, ethmoidal or frontal sinuses 
• T4d: intracranial spread 
 
Regional Lymph Nodes (N) 
• NX: involvement of lymph nodes not assessed 
• N0: no evidence of lymph node involvement 
• N1: involvement of ipsilateral regional lymph nodes 
• N2: involvement of contralateral or bilateral regional lymph nodes 
• N3: involvement of peripheral lymph nodes not draining ocular adnexal region 
• N4: involvement of central lymph nodes 
Note: regional lymph nodes include preauricular (parotid), submandibular and cervical 
 
Distant Metastasis (M) 
• M0: no evidence of involvement of other extranodal sites 
• M1a: noncontiguous involvement of tissues or organs external to the ocular adnexa (e.g. parotid glands, 
submandibular gland, lung, liver, spleen, kidney, breast, etc.) 
• M1b: lymphomatous involvement of the bone marrow 
• M1c: both M1a and M1b involvement 
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disease progression based on histology, tumor site, and patient risk factors, treatment is 
highly individualized for each patient.10  
 
  
Radiation therapy (RT) is the mainstay of treatment for most localized, low-grade 
OLs. RT can be used to eradicate the tumor or decrease tumor site prior to surgical 
excision. In patients with high grade lymphomas, RT may be used in conjunction with 
systemic chemotherapy to control the disease. In patients with MALT lymphoma RT is 
used as monotherapy in 70% of cases.10 Radiation doses vary based on various factors, 
but most patients are treated using a total dosage ranging between 20-54 Gy, delivered in 
small fractions of 2 Gy. This therapy historically received excellent local control in over 
90% of patients.10 Recently, there has been a push to decrease the total amount of 
radiation in indolent lymphomas to 4 Gy in 2x2 Gy fractions due to evidence indicating 
that excellent local control can be achieved with lower doses.25 Ocular side effects of 
high dose radiation to the orbit include cataracts, cutaneous reactions, 
keratoconjunctivitis sicca, and retinopathy.10 
 
 Chemotherapy is often used for OLs when the disease is either high grade (such 
as in DLBCL or MCL) and/or is disseminated. Combination regimens include CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone), hyper-CVAD 
(cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and 
cytarabine) and CVP (cyclophosphamide, vincristine, and prednisone).10  
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 Immunotherapy is an emerging modality in the treatment of OLs. The anti-CD20 
antibody Rituximab is commonly used in treating B cell lymphomas by preventing 
cellular proliferation, activation, differentiation and signal transduction. Since its 
introduction in the 1990s, Rituximab has significantly improved outcomes in lymphomas 
– in OLs, the combination of Rituximab and chemotherapy is associated with improved 
outcomes in patients with FL, MCL, and DLBCL.10 
 
Prognosis  
 Collecting accurate data on long term prognosis in OL is challenging due to the 
rarity of the disease and a paucity of long-term follow-up studies of patients. To date, the 
patient’s histological subtype of OL is the most important prognostic factor. Lower grade 
histologies such as MALT lymphoma show excellent remission rates of 100/120 patients 
in a large cohort study, whereas higher grade histologies have worse remissions of 26/33 
patients. Furthermore, in these patients, long term survival data was not available.10 In the 
largest retrospective cohort study of OL conducted by Olsen and colleagues, 797 patients 
from 7 eye centers globally were included. Their analysis showed that MALT and FL 
lymphoma had much better long term prognosis (10 year disease specific survival of 92% 
and 71% respectively) compared to the more aggressive DLBCL and MCL histologies 
(10 year disease specific survival of 41% and 32% respectively).11  
 
Statement of Purpose  
 The purpose of this thesis project is to elucidate prognostic factors in OL using 
the Surveillance, Epidemiology and End Results (SEER) database. In doing so, the aim is 
 24 
to provide better prognostication data for patients suffering from this disease using the 
largest ever cohort of patients with orbital lymphoma studied to date in the United States.  
 
Specifically, the three main objectives of this study are: 
1. Describe the epidemiology of OLs across various histologies in the United States 
2. Determine overall and disease specific survival amongst various OL histologies 
3. Determine whether other factors related to patient demographics or treatment 
affect prognoses 
 
We hope that our research will facilitate understanding the epidemiology and 
outcomes of this rare disease and can help physicians communicate disease prognoses 
more accurately and in an evidence-based manner to their patients depending on the 






Database and Disease Coding 
We determined our study population by searching the November 2016 submission 
of the SEER database for all cases of Extranodal Non-Hodgkin’s Lymphoma in the orbit 
(International Classification of Diseases 10 diagnosis code: C69.6). SEER first began 
collecting data on cancer cases on January 1, 1973, in Connecticut, Iowa, New Mexico, 
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Utah, and Hawaii and the metropolitan areas of Detroit and San Francisco-Oakland. 
Since then, it has gradually increased its coverage and has included Seattle, Atlanta, Los 
Angeles, Alaska, rural Georgia, Kentucky, Louisiana and New Jersey. Overall, the 
geographic coverage of the database accounts for 27.8% of the overall US population.27 
 
The following histologic subtypes were queried: follicular lymphoma (FL - ICD-
O-3: 9695/3, 9690/3, 9691/3, 9698/3), extranodal marginal zone lymphoma of mucosal 
associated lymphoid tissue (MALT - ICD-O-3: 9699/3), diffuse large B cell lymphoma 
(DLBCL - ICD-O-3: 9680/3, 9684/3), lymphoplasmacytic lymphoma (LPL - ICD-O-
3:9671/3), small lymphocytic lymphoma (SLL - ICD-O-3: 9670/3) and mantle cell 
lymphoma (MCL - ICD-O-3: 9673/3). Cases were diagnosed between January 1st, 1973 
and December 31st, 2014. Cases diagnosed at autopsy, or those that presented with 
multiple neoplasms were excluded.  
 
Study Variables  
Data on survival, outcome, surgical procedure, radiation therapy, chemotherapy, 
age at diagnosis, sex, and race were queried. Data on Ann-Arbor staging and TNM 
staging was sparse in the database and thus not included. Surgical procedures were 
grouped as follows: no surgery performed (SEER codes: 00), Unknown/other (SEER 
codes: 90,99,27,13,10,14), or orbitotomy with biopsy (SEER codes: 
20,22,23,24,25,26,27,30,41,50,60). For specifics on SEER procedure codes, see table 4. 
Radiation therapy and chemotherapy was grouped into ‘yes’ and ‘no/unknown.’  Of note, 
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the SEER database did not provide information on the specific types, dosages or 





00 None; no surgery of primary site; autopsy ONLY 
10 
   11 
   12 
   13 
   14 
Local tumor destruction, NOS 
   Photodynamic therapy  
   Electrocautery  
   Cryosurgery  
   Laser 
20  
   26 
   27 
 
 
      21 
      22 
      23 
      24 
     
  25 
Local tumor excision, NOS 
   Polypectomy 
   Excisional biopsy  
 
Any combination of 20 or 26-27 WITH 
      Photodynamic therapy 
      Electrocautery 
      Cryosurgery 
      Laser ablation 
 
   Laser excision  
30 Simple/partial surgical removal of primary site 
40 
   41 
Total surgical removal of primary site; enucleation 
   Total enucleation  
50 Surgery stated to be ‘de-bulking’ 
60 Radical surgery  
90 Surgery, NOS 
99 Unknown if surgery performed death certificate ONLY 
 
Table 4: SEER surgical codes for the Eye. NOS = Not otherwise specified 
Statistical Analysis  
 We computed patient demographic and treatment characteristics using descriptive 
statistics such as the ANOVA, chi-squared test and Fisher’s exact test. Univariate 
survival analysis was conducted using Kaplan-Meier survival models and log-rank tests. 
A Cox proportional hazards regression was used to determine factors affecting overall 
survival, including age, sex, race, histology and treatment. Age was dichotomized as 
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above or below 60 years, per the recommendation of the International Prognostic Index 
model for non-Hodgkin lymphoma.28 Analysis was conducted using RStudio version 1.0 
(RStudio, Inc., Boston, MA), with cutoffs for significance defined at p<0.05. 
 
Statement of Exemption and Compliance 
This study was compliant with HIPAA, adhered to the tenets of the Declaration of 
Helsinki and was approved by the Yale University Institutional Review Board as being 




Epidemiology of Orbital Lymphomas 
We identified 1504 patients across 6 lymphoma histologic subtypes (Table 5). 
Patients had a mean age of 66 years, which did not significantly vary amongst histologic 
subtypes.  There were slightly more cases of females (53%) diagnosed with OL than 
males (800 versus 704, sex-ratio: 1.13). This trend was also observed in every histology 
except in the case of MCL, where males accounted for 48/74 cases (64.9%, p = 0.023, see 
Table 5).  Race did not differ significantly amongst histological subtypes (Table 5), and 
1,233 (82%) patients in the cohort were white. 
 
 Number of Cases (%)  
Characteristic MALT  DLBCL FL SLL MCL LPL P Value 
















Male 344 (46.2) 140 (47.6) 83 (40.7) 67 (46.9) 48 (64.9) 22 (48.9) 0.023 
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Race        
White 585 (78.6) 248 (84.4) 174 (85.3) 121 
(84.6) 
63 (85.1) 37 (82.2) 0.052 
Black 54 (7.3) 18 (6.1) 16 (7.8) 2 (1.4) 6 (8.1) 2 (4.4) 
Other 91 (12.2) 25 (8.5) 11 (5.4) 18 (12.6) 4 (5.4) 6 (13.3) 
Unknown 14 (1.9) 3 (1.0) 3 (1.5) 2 (1.4) 1 (1.4) 0 (0) 




284 (38.2) 87 (29.6) 82 (40.2) 21 (14.7) 17 (23.0) 6 (13.3) <0.001 
Unknown/
Other 
41 (5.5) 72 (24.5) 41 (20.1) 87 (60.8) 22 (29.7) 26 (57.8) 
No 
Surgery 
419 (56.3) 135 (45.9) 81 (39.7) 35 (24.4) 35 (47.3) 13 (28.9) 
Radiation  479 (64.3) 161 (54.8) 115 (56.4) 99 (30.8) 41 (55.4) 31 (31.1) 0.005 
Chemotherapy  123 (16.5) 182 (61.9) 68 (33.3) 22 (15.4) 30 (40.5) 8 (17.8) <0.001 
Table 5: Baseline demographic characteristics 
 
Treatment Choices  
There were differences in the choice of surgical intervention chosen for patients 
with different histological subtypes (Table 5). Radiotherapy was the treatment of choice 
in 926 (61.6%) patients with OL. Patients with MALT lymphoma were most likely to 
receive radiation therapy (479/745 patients, 64.3%), whereas those with SLL were the 
least likely to have radiation therapy (99/143 patients, 30.8%). Chemotherapy was most 
commonly administered to patients with DLBCL (182/294 patients, 61.9%) and least 
likely given to those with SLL, the nodal form of chronic lymphocytic leukemia (22/143 
patients, 15.4%). 
 
Survival and Outcomes 
 Table 6 provides data on cancer specific survival probabilities amongst various 
histologic subtypes. MALT lymphoma conferred the best prognosis (10-year cancer 
specific survival [CSS] 90.2%, 95% Confidence Interval [CI] 87.4% – 93.1%) and 
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DLBCL conferred the worst prognosis (10-year CSS 68.6%, 95% CI 62.5% – 75.3%) 
(p<0.001, log-rank test). Upon pair-wise comparisons, DLBCL conferred a significantly 
worse overall survival compared to every other histology, except for MCL and LPL 
(p<0.05, log-rank test). Not only did DLBCL confer the worst cancer specific survival, 
but also the worst overall survival at 10 years (disease specific survival 44.6%, 95% CI 
38.5%-51.7%). Figure 3 shows Kaplan Meier plots of overall and cancer specific survival 
amongst the histologic subtypes. 
Cox proportional hazards regression showed that older age (Hazard Ratio [HR]: 3.71, 
95% Confidence Interval [CI]: 2.94-4.66, p<0.001), male sex (HR: 1.22, 95% CI: 1.039-
1.441, p = 0.015) and no radiation (HR: 1.72, 95% CI: 1.46-2.02, p<0.001) conferred a 
worse prognosis after controlling for the various histologic subtypes (Figure 4). The 





 Survival Percentage (95% Confidence Interval) 
Histology  1 year  5 year 10 year 
MALT Lymphoma 98.9 (98.1 – 99.6) 94.5 (92.7 – 96.4) 90.2 (87.4 – 93.1) 
Diffuse Large B Cell 
Lymphoma 
84.5 (80.3 – 88.9) 72.7 (67.2 – 78.5) 68.6 (62.5 – 75.3) 
Follicular 
Lymphoma 
97.4 (95.2 – 99.7) 88.9 (84.2 – 94.0) 82.7 (76.1 – 89.8) 
Small Lymphocytic 
Lymphoma 
97.2 (94.5 – 99.9) 94.3 (90.5 – 98.2) 88.9 (83.5 – 94.6) 
Mantle Cell 
Lymphoma 
95.9 (91.4 – 100) 82.8 (73.9 – 92.7) 71.0 (59.5 – 84.8) 
Lymphoplasmacytic 
Lymphoma 
100 (100 – 100) 95.2 (89.0 – 100) 84.5 (72.6 – 98.3) 
Table 6: Cancer specific survival probabilities by histologic subtype of OL 
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Figure 3: Kaplan-Meier plot of overall cumulative survival and cancer specific cumulative survival for 








In the largest cohort study performed on OL, our results demonstrate that 
histology is a significant predictor of survival.   Large analysis of histology and prognosis 
exist for lymphomas in other sites, including the gastrointestinal tract and thyroid, 
however, with the exception of the Olsen study, are lacking in the literature on orbital 
lymphoma.29–31 To date, this is the first study to compare the long-term survival amongst 
the numerous histologic subtypes of OL in the United States.  Our results confirm 
survival outcomes reported previously in the literature for specific histological 
subtypes.10–12,32  
 
The Effect of Disease Histology on Survival  
Our finding of the poor prognosis associated with DLBCL mirrors results 
reported by Olsen et al, who found DLBCL to confer a 10-year CSS of 41% in their 
cohort. However, we demonstrated that in the United States, DLBCL had a 10-year CSS 
of 68.6%. Furthermore, Olsen et al observed a 10-year CSS of only 32% for MCL, which 
contrasts our reported 10-year CSS of 71%. The decrease in CSS could be due to the 
advanced Ann Arbor Stage IV E in their cohort which included 29% DLBCL and 76% 
MCL.  Due to inherent limitations in the SEER database, our cohort lacked staging 
information, thus it was not possible to directly compare survival rates. However, it 
should be noted that for other lower grade histologies such as MALT and FL, the vast 
majority of diseases documented in the literature are Ann Arbor Stage I E. Therefore, 
assuming that the SEER database had a similar distribution of Ann Arbor staged cases as 
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the general population amongst patients with low grade histological subtypes of disease, 
our results are representative of what is found previously in the literature for these 
subtypes of disease. Furthermore, Olsen et al have previously reported in their studies 
that disease histologies have the most significant impact on prognosis, regardless of 
staging using the Ann Arbor or TNM system.10 Given this observation, our findings are 
valuable even in the absence of staging data in our study. 
 
While further prospective confirmatory studies are needed to understand the 
mechanistic basis of our results, the comparative survival amongst OL with varying 
histology is of clinical relevance. In addition to existing systems for staging, our results 
provide additional prognostic information that can be used to guide patient expectations. 
DLBCL is a high-grade aggressive malignancy, whereas MALT lymphoma is low-
grade.29,33 In the orbit, these histologic subtypes confer the worst and best prognoses 
respectively.  
Epidemiological Findings   
MALT lymphoma, which portends the best prognosis, presents more commonly 
in women and is most commonly found in the fifth decade. These results have been 
previously demonstrated in many smaller cohorts.4,5,8,34–36. We found that MCL of the 
ocular adnexal region manifests primarily in elderly males, and our findings confirm 
other published reports.11,37   Ahmed et al observed no difference in gender on survival in 
a subgroup analysis of DLBCL.32 Though our results demonstrated that male gender 
independently confers a worse prognosis in OL, this was not a matched controlled study 
and thus our results are difficult to generalize to the general population. 
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The Effects of Treatments on Survival  
We also observed that surgery and chemotherapy did not confer any significant 
effect on survival. Since the SEER database did not distinguish the exact type of surgery 
performed, it is hard to interpret the lack of survival differences seen in our study. Since 
orbitotomy surgeries also included biopsies, it could be possible that the majority of 
surgeries performed in our study were only biopsies, which would not confer any effect 
on survival. Similarly, the lack of survival difference between patients receiving 
chemotherapy versus those who did not could be confounded by the lack of staging data: 
it may be possible that patients receiving chemotherapy group had more advanced disease 
than those who did not. 
 
Lastly, we also observed that patients who received radiation had better outcomes 
compared to those whose radiation status was unknown or negative. Although radiation is 
a significant component of effective treatment for OL, our dataset does not provide any 
details on the type, extent or frequency of radiation therapy nor the lymphoma staging of 
the patients to whom it was administered. Since radiation therapy is typically utilized for 
less aggressive stages of orbital lymphoma, our results may be confounded by more 
patients with less aggressive lymphoma being treated with radiation. 
 
Study Limitations 
 There are inherent limitations when using the SEER database. Although the SEER 
database is the largest national collection of data on cancers across multiple health 
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systems, it has restricted data and does not provide information about clinical course, lab 
values, or detailed radiation, type of surgery and chemotherapy information. In the 
current database used for this analysis, it was not possible to assess the percentage of 
lymphoma from the orbit with conjunctival extension, laterality, and disease recurrence, 
which could have been confounding variables. Furthermore, data on AJCC and Ann 
Arbor Staging was not available, which is important in disease prognostication.  In 
addition, over the course of the 41-year study period, our cohort has a higher frequency 
of Small Lymphocytic Lymphoma cases compared to other multicenter trials. This may 
have occurred due to the variation in histologic classification at the time of diagnosis 
spanning four decades. Since histologic data was provided through the database, it is not 
possible to confirm the reclassification of our cases in the database according to the 
current World Health Organization Classification of Tumors of Hematopoietic and 
Lymphoid Tissues.38 However, in the case of rare diseases like OL, performing large 
prospective studies is not possible, and hence studies are restricted to retrospective 
analysis of large databases or individual cases.39   
Conclusion  
This SEER database analysis confirms known prognostic information on orbital 
lymphoma using the largest cohort of patients to date. Specifically, we demonstrate that 
histology is a significant predictor of survival in OL, with DLBCL conferring the worst 
prognosis (OS: 44.6% at 10 years) and MALT lymphoma conferring the best prognosis 
(OS: 64.9% at 10 years), while fully acknowledging the limitations of the SEER 
database. Although age, gender, and the use of radiation treatment are associated with 
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differing outcomes, further studies are needed to elucidate the mechanisms governing 
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